Free Trial
NASDAQ:PBYI

Puma Biotechnology (PBYI) Stock Price, News & Analysis

$4.15
-0.08 (-1.89%)
(As of 12:04 PM ET)
Today's Range
$4.06
$4.23
50-Day Range
$4.10
$5.83
52-Week Range
$2.13
$7.73
Volume
80,607 shs
Average Volume
529,751 shs
Market Capitalization
$200.19 million
P/E Ratio
12.58
Dividend Yield
N/A
Price Target
$7.00

Puma Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
68.7% Upside
$7.00 Price Target
Short Interest
Healthy
8.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Puma Biotechnology in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
26.09%
From $0.23 to $0.29 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Medical Sector

187th out of 921 stocks

Pharmaceutical Preparations Industry

72nd out of 426 stocks

PBYI stock logo

About Puma Biotechnology Stock (NASDAQ:PBYI)

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

PBYI Stock Price History

PBYI Stock News Headlines

Puma Biotechnology (NASDAQ:PBYI) Given Buy Rating at HC Wainwright
PBYI Crosses Above Average Analyst Target
See More Headlines
Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
5/23/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PBYI
Employees
185
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+65.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$21.59 million
Pretax Margin
7.29%

Debt

Sales & Book Value

Annual Sales
$235.60 million
Cash Flow
$0.71 per share
Book Value
$1.06 per share

Miscellaneous

Free Float
36,806,000
Market Cap
$204.06 million
Optionable
Optionable
Beta
1.31
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

PBYI Stock Analysis - Frequently Asked Questions

Should I buy or sell Puma Biotechnology stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings
or view top-rated stocks.

What is Puma Biotechnology's stock price target for 2024?

1 analysts have issued 1-year target prices for Puma Biotechnology's stock. Their PBYI share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 68.7% from the stock's current price.
View analysts price targets for PBYI
or view top-rated stocks among Wall Street analysts.

How have PBYI shares performed in 2024?

Puma Biotechnology's stock was trading at $4.33 at the start of the year. Since then, PBYI stock has decreased by 4.2% and is now trading at $4.15.
View the best growth stocks for 2024 here
.

When is Puma Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our PBYI earnings forecast
.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) announced its earnings results on Thursday, February, 29th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.07. The biopharmaceutical company had revenue of $72.20 million for the quarter, compared to analyst estimates of $73.22 million. Puma Biotechnology had a net margin of 6.79% and a trailing twelve-month return on equity of 35.49%.

What guidance has Puma Biotechnology issued on next quarter's earnings?

Puma Biotechnology updated its second quarter 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $45.5 million-$48.0 million, compared to the consensus revenue estimate of $57.3 million.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.24%), Acadian Asset Management LLC (4.06%), Athyrium Capital Management LP (2.60%), Sei Investments Co. (0.60%), GSA Capital Partners LLP (0.39%) and Rice Hall James & Associates LLC (0.29%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Langley Steinert, Maximo F Nougues, Michael Patrick Miller and Troy Edward Wilson.
View institutional ownership trends
.

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PBYI) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners